APO-CEFPROZIL POWDER FOR SUSPENSION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
03-06-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CEFPROZIL
Tillgänglig från:
APOTEX INC
ATC-kod:
J01DC10
INN (International namn):
CEFPROZIL
Dos:
125MG
Läkemedelsform:
POWDER FOR SUSPENSION
Sammansättning:
CEFPROZIL 125MG
Administreringssätt:
ORAL
Enheter i paketet:
75ML/100ML
Receptbelagda typ:
Prescription
Terapiområde:
SECOND GENERATION CEPHALOSPORINS
Produktsammanfattning:
Active ingredient group (AIG) number: 0127613001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2007-04-19
Produktens egenskaper
Page 1 of 27
PRODUCT MONOGRAPH
PR
APO-CEFPROZIL
Cefprozil for Oral Suspension, USP
125 mg and 250 mg Cefprozil (on anhydrous basis) / 5 mL
Antibiotic
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
June 3, 2020
Toronto, Ontario
M9L 1T9
Control No: 235590
Page 2 of 27
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................................
3
SUMMARY PRODUCT INFORMATION
......................................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................................
3
CONTRAINDICATIONS
.................................................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................................
6
DRUG INTERACTIONS
.................................................................................................................................
7
DOSAGE AND ADMINISTRATION
.............................................................................................................
8
OVERDOSAGE
................................................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................................
10
STORAGE AND STABILITY
.......................................................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................................................
11
PART II: SCIENTIFIC INFORMATION
.......................................................
Läs hela dokumentet
